https://www.selleckchem.com/products/td139.html
Available essential tremor (ET) therapies have limitations. The objective of this study was to evaluate CX-8998, a selective T-type calcium channel modulator, in essential tremor. Patients 18-75 years old with moderate to severe essential tremor were randomized 11 to receive CX-8998 (titrated to 10 mg twice daily) or placebo. The primary end point was change from baseline to day 28 in The Essential Tremor Rating Assessment Scale performance subscale scored by independent blinded video raters. Secondary outcomes included in-person blinded
Curtir
Comentario
Compartilhar
